Small changes can make a big difference - MicroRNA regulation of cardiac hypertrophy

Journal of Molecular and Cellular Cardiology

Volumn 52, Issue 1, 2012, Pages 74-82

  Gladka, Monika M ^a   da Costa Martins, Paula A ^a   De Windt, Leon J ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Cardiac hypertrophy; Gene expression; MicroRNA; Posttranscriptional regulation; Signaling

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; APOPTOSIS SIGNAL REGULATING KINASE 1; CALCINEURIN; CALMODULIN; COLLAGEN TYPE 1; COLLAGEN TYPE 3; CYCLIN D2; CYCLOSPORIN A; ELASTIN; FIBRILLIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MICRORNA; MITOGEN ACTIVATED PROTEIN KINASE; MYOCARDIN; MYOSIN HEAVY CHAIN; MYOSIN HEAVY CHAIN ALPHA; MYOSIN HEAVY CHAIN BETA; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN CDC42; PROTEIN KINASE B; RAS PROTEIN; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; SOMATOMEDIN C; SPROUTY PROTEIN; THIOREDOXIN 1; TRANSCRIPTION FACTOR FKHRL1; TRANSCRIPTION FACTOR NFAT; UNINDEXED DRUG;

CELL COMMUNICATION; DRUG EFFECT; GENE EXPRESSION REGULATION; HEART FAILURE; HEART MUSCLE CELL; HEART MUSCLE FIBROSIS; HEART VENTRICLE HYPERTROPHY; HUMAN; INTRACELLULAR SIGNALING; NONHUMAN; PRIORITY JOURNAL; REVIEW; SARCOMERE; SIGNAL TRANSDUCTION; UBIQUITINATION;

ANIMALS; CARDIOMEGALY; FIBROSIS; GENE EXPRESSION REGULATION; HUMANS; MICRORNAS; MYOCARDIAL CONTRACTION; SIGNAL TRANSDUCTION; UBIQUITINATION;

EID: 84155180949     PISSN: 00222828     EISSN: 10958584     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2011.09.015     Document Type: Review

References (76)

1. Towbin J.A., Bowles N.E. The failing heart. Nature 2002, 415:227-233.
2. Xing W., Zhang T.C., Cao D., Wang Z., Antos C.L., Li S., et al. Myocardin induces cardiomyocyte hypertrophy. Circ Res 2006, 98:1089-1097.
3. Small E.M., Warkman A.S., Wang D.Z., Sutherland L.B., Olson E.N., Krieg P.A. Myocardin is sufficient and necessary for cardiac gene expression in Xenopus. Development 2005, 132:987-997.
4. Katz A.M. The cardiomyopathy of overload: an unnatural growth response. Eur Heart J 1995, 16(Suppl O):110-114.
5. Meijs M.F., de Windt L.J., de Jonge N., Cramer M.J., Bots M.L., Mali W.P., et al. Left ventricular hypertrophy: a shift in paradigm. Curr Med Chem 2007, 14:157-171.
6. Obad S., dos Santos C.O., Petri A., Heidenblad M., Broom O., Ruse C., et al. Silencing of microRNA families by seed-targeting tiny LNAs. Nat. Genet.43:371-378.
7. Bartel D.P. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004, 116:281-297.
8. Bartel D.P. MicroRNAs: target recognition and regulatory functions. Cell 2009, 136:215-233.
9. Small E.M., Olson E.N. Pervasive roles of microRNAs in cardiovascular biology. Nature 2011, 469:336-342.
10. da Costa Martins P.A., Leptidis S., Salic K., De Windt L.J. MicroRNA regulation in cardiovascular disease. Curr Drug Targets.11:900-906.
11. Cai X., Hagedorn C.H., Cullen B.R. Human microRNAs are processed from capped, polyadenylated transcripts that can also function as mRNAs. RNA 2004, 10:1957-1966.
12. Chendrimada T.P., Gregory R.I., Kumaraswamy E., Norman J., Cooch N., Nishikura K., et al. TRBP recruits the Dicer complex to Ago2 for microRNA processing and gene silencing. Nature 2005, 436:740-744.
13. Fiedler J., Gupta S.K., Thum T. Identification of cardiovascular microRNA targetomes. J Mol Cell Cardiol 2011.
14. van Rooij E., Sutherland L.B., Thatcher J.E., DiMaio J.M., Naseem R.H., Marshall W.S., et al. Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis. Proc Natl Acad Sci USA 2008, 105:13027-13032.
15. Xu N., Papagiannakopoulos T., Pan G., Thomson J.A., Kosik K.S. MicroRNA-145 regulates OCT4, SOX2, and KLF4 and represses pluripotency in human embryonic stem cells. Cell 2009, 137:647-658.
16. Zampetaki A., Kiechl S., Drozdov I., Willeit P., Mayr U., Prokopi M., et al. Plasma microRNA profiling reveals loss of endothelial miR-126 and other microRNAs in type 2 diabetes. Circ Res 2010, 107:810-817.
17. Bernstein E., Kim S.Y., Carmell M.A., Murchison E.P., Alcorn H., Li M.Z., et al. Dicer is essential for mouse development. Nat Genet 2003, 35:215-217.
18. Zhao Y., Ransom J.F., Li A., Vedantham V., von Drehle M., Muth A.N., et al. Dysregulation of cardiogenesis, cardiac conduction, and cell cycle in mice lacking miRNA-1-2. Cell 2007, 129:303-317.
19. Saxena A., Tabin C.J. miRNA-processing enzyme Dicer is necessary for cardiac outflow tract alignment and chamber septation. Proc Natl Acad Sci USA 2010, 107:87-91.
20. Chen J.F., Murchison E.P., Tang R., Callis T.E., Tatsuguchi M., Deng Z., et al. Targeted deletion of Dicer in the heart leads to dilated cardiomyopathy and heart failure. Proc Natl Acad Sci USA 2008, 105:2111-2116.
21. da Costa Martins P.A., Bourajjaj M., Gladka M., Kortland M., van Oort R.J., Pinto Y.M., et al. Conditional dicer gene deletion in the postnatal myocardium provokes spontaneous cardiac remodeling. Circulation 2008, 118:1567-1576.
22. Rao P.K., Toyama Y., Chiang H.R., Gupta S., Bauer M., Medvid R., et al. Loss of cardiac microRNA-mediated regulation leads to dilated cardiomyopathy and heart failure. Circ Res 2009, 105:585-594.
23. Naga Prasad S.V., Duan Z.H., Gupta M.K., Surampudi V.S., Volinia S., Calin G.A., et al. Unique microRNA profile in end-stage heart failure indicates alterations in specific cardiovascular signaling networks. J Biol Chem 2009, 284:27487-27499.
24. Thum T., Galuppo P., Wolf C., Fiedler J., Kneitz S., van Laake L.W., et al. MicroRNAs in the human heart: a clue to fetal gene reprogramming in heart failure. Circulation 2007, 116:258-267.
25. Liu N., Williams A.H., Kim Y., McAnally J., Bezprozvannaya S., Sutherland L.B., et al. An intragenic MEF2-dependent enhancer directs muscle-specific expression of microRNAs 1 and 133. Proc Natl Acad Sci USA 2007, 104:20844-20849.
26. Zhao Y., Samal E., Srivastava D. Serum response factor regulates a muscle-specific microRNA that targets Hand2 during cardiogenesis. Nature 2005, 436:214-220.
27. McCarthy J.J. MicroRNA-206: the skeletal muscle-specific myomiR. Biochim Biophys Acta 2008, 1779:682-691.
28. Liu N., Bezprozvannaya S., Williams A.H., Qi X., Richardson J.A., Bassel-Duby R., et al. microRNA-133a regulates cardiomyocyte proliferation and suppresses smooth muscle gene expression in the heart. Genes Dev 2008, 22:3242-3254.
29. Cheng Y., Ji R., Yue J., Yang J., Liu X., Chen H., et al. MicroRNAs are aberrantly expressed in hypertrophic heart: do they play a role in cardiac hypertrophy?. Am J Pathol 2007, 170:1831-1840.
30. Li Q., Song X.W., Zou J., Wang G.K., Kremneva E., Li X.Q., et al. Attenuation of microRNA-1 derepresses the cytoskeleton regulatory protein twinfilin-1 to provoke cardiac hypertrophy. J Cell Sci 2010, 123:2444-2452.
31. Wang Z., Lu Y., Yang B. MicroRNAs and atrial fibrillation: new fundamentals. Cardiovasc Res 2011, 89:710-721.
32. Elia L., Contu R., Quintavalle M., Varrone F., Chimenti C., Russo M.A., et al. Reciprocal regulation of microRNA-1 and insulin-like growth factor-1 signal transduction cascade in cardiac and skeletal muscle in physiological and pathological conditions. Circulation 2009, 120:2377-2385.
33. Ikeda S., He A., Kong S.W., Lu J., Bejar R., Bodyak N., et al. MicroRNA-1 negatively regulates expression of the hypertrophy-associated calmodulin and Mef2a genes. Mol Cell Biol 2009, 29:2193-2204.
34. Molkentin J.D., Lu J.R., Antos C.L., Markham B., Richardson J., Robbins J., et al. A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell 1998, 93:215-228.
35. Bourajjaj M., Armand A.S., da Costa Martins P.A., Weijts B., van der Nagel R., Heeneman S., et al. NFATc2 is a necessary mediator of calcineurin-dependent cardiac hypertrophy and heart failure. J Biol Chem 2008, 283:22295-22303.
36. van Oort R.J., van Rooij E., Bourajjaj M., Schimmel J., Jansen M.A., van der Nagel R., et al. MEF2 activates a genetic program promoting chamber dilation and contractile dysfunction in calcineurin-induced heart failure. Circulation 2006, 114:298-308.
37. Dong D.L., Chen C., Huo R., Wang N., Li Z., Tu Y.J., et al. Reciprocal repression between microRNA-133 and calcineurin regulates cardiac hypertrophy: a novel mechanism for progressive cardiac hypertrophy. Hypertension 2010, 55:946-952.
38. Rozich J.D., Barnes M.A., Schmid P.G., Zile M.R., McDermott P.J., Cooper G.T. Load effects on gene expression during cardiac hypertrophy. J Mol Cell Cardiol 1995, 27:485-499.
39. Wilkins B.J., De Windt L.J., Bueno O.F., Braz J.C., Glascock B.J., Kimball T.F., et al. Targeted disruption of NFATc3, but not NFATc4, reveals an intrinsic defect in calcineurin-mediated cardiac hypertrophic growth. Mol Cell Biol 2002, 22:7603-7613.
40. Care A., Catalucci D., Felicetti F., Bonci D., Addario A., Gallo P., et al. MicroRNA-133 controls cardiac hypertrophy. Nat Med 2007, 13:613-618.
41. Bergemann A.D., Cole F., Hirschhorn K. The etiology of Wolf-Hirschhorn syndrome. Trends Genet 2005, 21:188-195.
42. Wang D., Chang P.S., Wang Z., Sutherland L., Richardson J.A., Small E., et al. Activation of cardiac gene expression by myocardin, a transcriptional cofactor for serum response factor. Cell 2001, 105:851-862.
43. Wang K., Long B., Zhou J., Li P.F. miR-9 and NFATc3 regulate myocardin in cardiac hypertrophy. J Biol Chem 2010, 285:11903-11912.
44. Saitoh M., Nishitoh H., Fujii M., Takeda K., Tobiume K., Sawada Y., et al. Mammalian thioredoxin is a direct inhibitor of apoptosis signal-regulating kinase (ASK) 1. EMBO J 1998, 17:2596-2606.
45. Ago T., Sadoshima J. Thioredoxin and ventricular remodeling. J Mol Cell Cardiol 2006, 41:762-773.
46. Yang Y., Ago T., Zhai P., Abdellatif M., Sadoshima J. Thioredoxin 1 negatively regulates angiotensin II-induced cardiac hypertrophy through upregulation of miR-98/let-7. Circ Res 2011, 108:305-313.
47. Angelis E., Garcia A., Chan S.S., Schenke-Layland K., Ren S., Goodfellow S.J., et al. A cyclin D2-Rb pathway regulates cardiac myocyte size and RNA polymerase III after biomechanical stress in adult myocardium. Circ Res 2008, 102:1222-1229.
48. Busk P.K., Hinrichsen R., Bartkova J., Hansen A.H., Christoffersen T.E., Bartek J., et al. Cyclin D2 induces proliferation of cardiac myocytes and represses hypertrophy. Exp Cell Res 2005, 304:149-161.
49. van Rooij E., Sutherland L.B., Liu N., Williams A.H., McAnally J., Gerard R.D., et al. A signature pattern of stress-responsive microRNAs that can evoke cardiac hypertrophy and heart failure. Proc Natl Acad Sci USA 2006, 103:18255-18260.
50. Tatsuguchi M., Seok H.Y., Callis T.E., Thomson J.M., Chen J.F., Newman M., et al. Expression of microRNAs is dynamically regulated during cardiomyocyte hypertrophy. J Mol Cell Cardiol 2007, 42:1137-1141.
51. Thum T., Gross C., Fiedler J., Fischer T., Kissler S., Bussen M., et al. MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature 2008, 456:980-984.
52. Kim E.K., Choi E.J. Pathological roles of MAPK signaling pathways in human diseases. Biochim Biophys Acta 2010, 1802:396-405.
53. Roy S., Khanna S., Hussain S.R., Biswas S., Azad A., Rink C., et al. MicroRNA expression in response to murine myocardial infarction: miR-21 regulates fibroblast metalloprotease-2 via phosphatase and tensin homologue. Cardiovasc Res 2009, 82:21-29.
54. Cheng Y., Zhu P., Yang J., Liu X., Dong S., Wang X., et al. Ischaemic preconditioning-regulated miR-21 protects heart against ischaemia/reperfusion injury via anti-apoptosis through its target PDCD4. Cardiovasc Res 2010, 87:431-439.
55. Patrick D.M., Montgomery R.L., Qi X., Obad S., Kauppinen S., Hill J.A., et al. Stress-dependent cardiac remodeling occurs in the absence of microRNA-21 in mice. J Clin Invest 2010, 120:3912-3916.
56. Thum T., Chau N., Bhat B., Gupta S.K., Linsley P.S., Bauersachs J., et al. Comparison of different miR-21 inhibitor chemistries in a cardiac disease model. J Clin Invest 2011, 121:461-462. author reply 2-3.
57. da Costa Martins P.A., De Windt L.J. miR-21: a miRaculous Socratic paradox. Cardiovasc Res 2010, 87:397-400.
58. van Rooij E., Quiat D., Johnson B.A., Sutherland L.B., Qi X., Richardson J.A., et al. A family of microRNAs encoded by myosin genes governs myosin expression and muscle performance. Dev Cell 2009, 17:662-673.
59. Bell M.L., Buvoli M., Leinwand L.A. Uncoupling of expression of an intronic microRNA and its myosin host gene by exon skipping. Mol Cell Biol 2010, 30:1937-1945.
60. Kim H.J., Cui X.S., Kim E.J., Kim W.J., Kim N.H. New porcine microRNA genes found by homology search. Genome/ Natl Res Counc Can 2006, 49:1283-1286.
61. Wang J.X., Jiao J.Q., Li Q., Long B., Wang K., Liu J.P., et al. miR-499 regulates mitochondrial dynamics by targeting calcineurin and dynamin-related protein-1. Nat Med 2011, 17:71-78.
62. Callis T.E., Pandya K., Seok H.Y., Tang R.H., Tatsuguchi M., Huang Z.P., et al. MicroRNA-208a is a regulator of cardiac hypertrophy and conduction in mice. J Clin Invest 2009, 119:2772-2786.
63. Morkin E. Control of cardiac myosin heavy chain gene expression. Microsc Res Tech 2000, 50:522-531.
64. van Rooij E., Sutherland L.B., Qi X., Richardson J.A., Hill J., Olson E.N. Control of stress-dependent cardiac growth and gene expression by a microRNA. Science 2007, 316:575-579.
65. Tardiff J.C., Hewett T.E., Factor S.M., Vikstrom K.L., Robbins J., Leinwand L.A. Expression of the beta (slow)-isoform of MHC in the adult mouse heart causes dominant-negative functional effects. Am J Physiol Heart Circ Physiol 2000, 278:H412-H419.
66. Narolska N.A., Eiras S., van Loon R.B., Boontje N.M., Zaremba R., Spiegelen Berg S.R., et al. Myosin heavy chain composition and the economy of contraction in healthy and diseased human myocardium. J Muscle Res Cell Motil 2005, 26:39-48.
67. da Costa Martins P.A., Salic K., Gladka M.M., Armand A.S., Leptidis S., el Azzouzi H., et al. MicroRNA-199b targets the nuclear kinase Dyrk1a in an auto-amplification loop promoting calcineurin/NFAT signalling. Nat Cell Biol 2010, 12:1220-1227.
68. van Rooij E., Doevendans P.A., de Theije C.C., Babiker F.A., Molkentin J.D., de Windt L.J. Requirement of nuclear factor of activated T-cells in calcineurin-mediated cardiomyocyte hypertrophy. J Biol Chem 2002, 277:48617-48626.
69. Arron J.R., Winslow M.M., Polleri A., Chang C.P., Wu H., Gao X., et al. NFAT dysregulation by increased dosage of DSCR1 and DYRK1A on chromosome 21. Nature 2006, 441:595-600.
70. Gwack Y., Sharma S., Nardone J., Tanasa B., Iuga A., Srikanth S., et al. A genome-wide Drosophila RNAi screen identifies DYRK-family kinases as regulators of NFAT. Nature 2006, 441:646-650.
71. Song X.W., Li Q., Lin L., Wang X.C., Li D.F., Wang G.K., et al. MicroRNAs are dynamically regulated in hypertrophic hearts, and miR-199a is essential for the maintenance of cell size in cardiomyocytes. J Cell Physiol 2010, 225:437-443.
72. Sano M., Minamino T., Toko H., Miyauchi H., Orimo M., Qin Y., et al. p53-induced inhibition of Hif-1 causes cardiac dysfunction during pressure overload. Nature 2007, 446:444-448.
73. Rane S., He M., Sayed D., Vashistha H., Malhotra A., Sadoshima J., et al. Downregulation of miR-199a derepresses hypoxia-inducible factor-1alpha and Sirtuin 1 and recapitulates hypoxia preconditioning in cardiac myocytes. Circ Res 2009, 104:879-886.
74. Haghikia A., Missol-Kolka E., Tsikas D., Venturini L., Brundiers S., Castoldi M., et al. Signal transducer and activator of transcription 3-mediated regulation of miR-199a-5p links cardiomyocyte and endothelial cell function in the heart: a key role for ubiquitin-conjugating enzymes. Eur Heart J 2011, 32:1287-1297.
75. Busk P.K., Cirera S. MicroRNA profiling in early hypertrophic growth of the left ventricle in rats. Biochem Biophys Res Commun 2010, 396:989-993.
76. Hoofnagle M.H., Neppl R.L., Berzin E.L., Teg Pipes G.C., Olson E.N., Wamhoff B.W., et al. Myocardin is differentially required for the development of smooth muscle cells and cardiomyocytes. Am. J. Physiol. Heart Circ. Physiol. 2011, 300:H1707-H1721.